<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Percheron Therapeutics Limited — News on 6ix</title>
    <link>https://6ix.com/company/percheron-therapeutics-limited</link>
    <description>Latest news and press releases for Percheron Therapeutics Limited on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Tue, 14 Apr 2026 07:21:03 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/percheron-therapeutics-limited" rel="self" type="application/rss+xml" />
    <item>
      <title>Results of Entitlement Offer</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/results-of-entitlement-offer-57</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/results-of-entitlement-offer-57</guid>
      <pubDate>Tue, 14 Apr 2026 07:21:03 GMT</pubDate>
      <description>Results of Entitlement Offer</description>
    </item>
    <item>
      <title>Prospectus - Non-renounceable Entitlement Offer</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/prospectus-non-renounceable-entitlement-offer-3</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/prospectus-non-renounceable-entitlement-offer-3</guid>
      <pubDate>Mon, 16 Mar 2026 03:22:02 GMT</pubDate>
      <description>Prospectus - Non-renounceable Entitlement Offer</description>
    </item>
    <item>
      <title>Non-renounceable Entitlement Offer</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/non-renounceable-entitlement-offer-18</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/non-renounceable-entitlement-offer-18</guid>
      <pubDate>Mon, 16 Mar 2026 03:20:03 GMT</pubDate>
      <description>Non-renounceable Entitlement Offer</description>
    </item>
    <item>
      <title>Half Yearly Report and Accounts</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/half-yearly-report-and-accounts-525</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/half-yearly-report-and-accounts-525</guid>
      <pubDate>Thu, 26 Feb 2026 07:02:03 GMT</pubDate>
      <description>Half Yearly Report and Accounts</description>
    </item>
    <item>
      <title>Quarterly Activities/Appendix 4C Cash Flow Report</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/quarterly-activitiesappendix-4c-cash-flow-report-279</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/quarterly-activitiesappendix-4c-cash-flow-report-279</guid>
      <pubDate>Fri, 30 Jan 2026 03:07:05 GMT</pubDate>
      <description>Quarterly Activities/Appendix 4C Cash Flow Report</description>
    </item>
    <item>
      <title>Quarterly Activities Report and Appendix 4C</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/quarterly-activities-report-and-appendix-4c-71</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/quarterly-activities-report-and-appendix-4c-71</guid>
      <pubDate>Fri, 31 Oct 2025 02:18:24 GMT</pubDate>
      <description>Quarterly Activities Report and Appendix 4C</description>
    </item>
    <item>
      <title>Percheron Therapeutics Limited to Present at the Life Sciences Virtual Investor Forum September 18th</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/percheron-therapeutics-limited-present-life-123500505</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/percheron-therapeutics-limited-present-life-123500505</guid>
      <pubDate>Thu, 11 Sep 2025 12:35:00 GMT</pubDate>
      <description>Company invites individual and institutional investors, as well as advisors and analysts, to attend online at VirtualInvestorConferences.comMELBOURNE, Australia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Percheron Therapeutics Limited (ASX: PER | US OTC: PERCF), based in Melbourne, Australia and focused on the development of novel therapies for oncology and rare diseases, today announced that Dr James Garner, CEO and Managing Director, will present live at the Life Sciences Virtual Investor Forum hoste</description>
    </item>
    <item>
      <title>Appendix 4E and Annual Report</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/appendix-4e-and-annual-report-152</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/appendix-4e-and-annual-report-152</guid>
      <pubDate>Thu, 28 Aug 2025 07:54:12 GMT</pubDate>
      <description>Appendix 4E and Annual Report</description>
    </item>
    <item>
      <title>Percheron licenses HMBD-002 from Hummingbird Bioscience</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/percheron-licenses-hmbd-002-from-hummingbird-bioscience</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/percheron-licenses-hmbd-002-from-hummingbird-bioscience</guid>
      <pubDate>Thu, 26 Jun 2025 04:38:13 GMT</pubDate>
      <description>Percheron licenses HMBD-002 from Hummingbird Bioscience</description>
    </item>
    <item>
      <title>Hummingbird Bioscience Licenses HMBD-002, Phase II-Ready Anti-VISTA Monoclonal Antibody to Percheron Therapeutics</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/hummingbird-bioscience-licenses-hmbd-002-phase-ii-ready-anti-vista-monoclonal-antibody-to-percheron-therapeutics</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/hummingbird-bioscience-licenses-hmbd-002-phase-ii-ready-anti-vista-monoclonal-antibody-to-percheron-therapeutics</guid>
      <pubDate>Thu, 26 Jun 2025 01:00:00 GMT</pubDate>
      <description>Percheron Therapeutics obtains exclusive worldwide rights to Hummingbird Bioscience’s anti-VISTA mAb for further clinical development Hummingbird Bioscience stands to receive up to USD 290 million in upfront and milestone payments, plus royalties, from Percheron TherapeuticsPercheron Therapeutics aims to commence phase II clinical development of HMBD-002 in CY2026 SINGAPORE, June 26, 2025 (GLOBE NEWSWIRE) -- Hummingbird Bioscience, a biotherapeutics company discovering and developing transformat</description>
    </item>
    <item>
      <title>Trading Halt</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/trading-halt-1378</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/trading-halt-1378</guid>
      <pubDate>Wed, 25 Jun 2025 03:55:08 GMT</pubDate>
      <description>Trading Halt</description>
    </item>
    <item>
      <title>Response to ASX Query</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/response-to-asx-query-149</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/response-to-asx-query-149</guid>
      <pubDate>Thu, 06 Mar 2025 06:13:13 GMT</pubDate>
      <description>Response to ASX Query</description>
    </item>
    <item>
      <title>Letter From The Chair and Half Year Accounts</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/letter-from-the-chair-and-half-year-accounts</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/letter-from-the-chair-and-half-year-accounts</guid>
      <pubDate>Wed, 19 Feb 2025 05:51:04 GMT</pubDate>
      <description>Letter From The Chair and Half Year Accounts</description>
    </item>
    <item>
      <title>Topline Six-Month Results From Phase IIb Study of Avicursen</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/topline-six-month-results-from-phase-iib-study-of-avicursen</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/topline-six-month-results-from-phase-iib-study-of-avicursen</guid>
      <pubDate>Wed, 18 Dec 2024 03:46:08 GMT</pubDate>
      <description>Topline Six-Month Results From Phase IIb Study of Avicursen</description>
    </item>
    <item>
      <title>Clinical Trial Update</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/clinical-trial-update-3</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/clinical-trial-update-3</guid>
      <pubDate>Mon, 02 Dec 2024 03:24:20 GMT</pubDate>
      <description>Clinical Trial Update</description>
    </item>
    <item>
      <title>Results of Share Purchase Plan</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/results-of-share-purchase-plan-36</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/results-of-share-purchase-plan-36</guid>
      <pubDate>Wed, 13 Nov 2024 03:00:24 GMT</pubDate>
      <description>Results of Share Purchase Plan</description>
    </item>
    <item>
      <title>Percheron to launch Share Purchase Plan</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/percheron-to-launch-share-purchase-plan</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/percheron-to-launch-share-purchase-plan</guid>
      <pubDate>Wed, 23 Oct 2024 02:57:15 GMT</pubDate>
      <description>Percheron to launch Share Purchase Plan</description>
    </item>
    <item>
      <title>$13.0 million Institutional Placement</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/dollar130-million-institutional-placement</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/dollar130-million-institutional-placement</guid>
      <pubDate>Fri, 18 Oct 2024 02:44:25 GMT</pubDate>
      <description>$13.0 million Institutional Placement</description>
    </item>
    <item>
      <title>Completion of avicursen (ATL1102) toxicology study</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/completion-of-avicursen-atl1102-toxicology-study</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/completion-of-avicursen-atl1102-toxicology-study</guid>
      <pubDate>Mon, 30 Sep 2024 03:28:29 GMT</pubDate>
      <description>Completion of avicursen (ATL1102) toxicology study</description>
    </item>
    <item>
      <title>Phase IIb study of ATL1102 in DMD completes recruitment</title>
      <link>https://6ix.com/company/percheron-therapeutics-limited/news/phase-iib-study-of-atl1102-in-dmd-completes-recruitment</link>
      <guid isPermaLink="true">https://6ix.com/company/percheron-therapeutics-limited/news/phase-iib-study-of-atl1102-in-dmd-completes-recruitment</guid>
      <pubDate>Wed, 29 May 2024 03:22:27 GMT</pubDate>
      <description>Phase IIb study of ATL1102 in DMD completes recruitment</description>
    </item>
  </channel>
</rss>